CN104244952A - 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 - Google Patents

组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 Download PDF

Info

Publication number
CN104244952A
CN104244952A CN201380020595.0A CN201380020595A CN104244952A CN 104244952 A CN104244952 A CN 104244952A CN 201380020595 A CN201380020595 A CN 201380020595A CN 104244952 A CN104244952 A CN 104244952A
Authority
CN
China
Prior art keywords
abexinostat
salt
pazopanib
cancer
angiogenic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020595.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴拉苏布拉马尼安
T·D·莫迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CN104244952A publication Critical patent/CN104244952A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380020595.0A 2012-02-17 2013-02-15 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 Pending CN104244952A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600491P 2012-02-17 2012-02-17
US61/600,491 2012-02-17
US201261602544P 2012-02-23 2012-02-23
US61/602,544 2012-02-23
PCT/US2013/026462 WO2013123413A2 (en) 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Publications (1)

Publication Number Publication Date
CN104244952A true CN104244952A (zh) 2014-12-24

Family

ID=48984895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020595.0A Pending CN104244952A (zh) 2012-02-17 2013-02-15 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途

Country Status (12)

Country Link
US (1) US20150335609A1 (enExample)
EP (1) EP2814493A4 (enExample)
JP (1) JP2015507020A (enExample)
KR (1) KR20140129164A (enExample)
CN (1) CN104244952A (enExample)
AU (1) AU2013221298A1 (enExample)
CA (1) CA2864736A1 (enExample)
HK (1) HK1204998A1 (enExample)
MX (1) MX2014009892A (enExample)
RU (1) RU2014137190A (enExample)
SG (1) SG11201404888SA (enExample)
WO (1) WO2013123413A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303231A1 (en) * 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
LT3325623T (lt) 2015-07-23 2019-10-25 Inst Curie Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti
WO2017053823A1 (en) * 2015-09-25 2017-03-30 Pharmacyclics Llc Treatment using hdac inhibitors and immunotherapy
WO2018195446A1 (en) * 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
JP7227777B2 (ja) * 2019-02-04 2023-02-22 キヤノン株式会社 撮像装置
KR20220018727A (ko) 2020-08-07 2022-02-15 계명대학교 산학협력단 파조파닙 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물
US20240075031A1 (en) * 2020-12-07 2024-03-07 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074936A2 (en) * 2008-12-15 2010-07-01 Eli Lilly And Company Enzastaurin for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328819T3 (es) * 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
WO2005105094A2 (en) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Cancer treatment method
SI1954281T1 (sl) * 2005-11-29 2011-06-30 Glaxosmithkline Llc Postopek zdravljenja raka
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
MX2013008654A (es) * 2011-01-26 2013-09-02 Glaxosmithkline Intellectual Property Ltd Combinaciones.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074936A2 (en) * 2008-12-15 2010-07-01 Eli Lilly And Company Enzastaurin for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GONZALO LOPEZ ET AL.: "Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma. Gonzalo Lopez et al. Clin Cancer Res. 2009,第15卷第10期，第3472-3483页", 《CLIN CANCER RES》, vol. 15, no. 10, 15 May 2009 (2009-05-15), pages 3472 - 3483 *
THOMAS S ET AL: "The HDAC inhibitor PCI-24781 poteniates the anti-tumor activity of tamoxifen in ER-positive breast cancer cells", 《CANCER RESEARCH》, vol. 71, no. 8, 31 December 2011 (2011-12-31), pages 1 - 2 *

Also Published As

Publication number Publication date
WO2013123413A2 (en) 2013-08-22
CA2864736A1 (en) 2013-08-22
EP2814493A2 (en) 2014-12-24
KR20140129164A (ko) 2014-11-06
SG11201404888SA (en) 2014-09-26
HK1204998A1 (en) 2015-12-11
US20150335609A1 (en) 2015-11-26
EP2814493A4 (en) 2015-07-22
AU2013221298A1 (en) 2014-08-28
JP2015507020A (ja) 2015-03-05
RU2014137190A (ru) 2016-04-10
MX2014009892A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
CN103917231B (zh) 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
US10105552B2 (en) Formulations of histone deacetylase inhibitor and uses thereof
ES3017250T3 (en) Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
ES2380704T3 (es) Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
CN104244952A (zh) 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
ES2574627T3 (es) Formas de administración farmacéuticas que comprenden 5-cloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
US9867865B1 (en) Mesalamine for the treatment of cancer
KR20220029717A (ko) 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템
US10857113B2 (en) Bezafibrate for the treatment of cancer
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
HK1200095B (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204998

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Illinois State

Applicant after: PHARMACYCLICS, Inc.

Address before: California, USA

Applicant before: PHARMACYCLICS, Inc.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160901

Address after: California, USA

Applicant after: PHARMACYCLICS LLC

Address before: Illinois State

Applicant before: PHARMACYCLICS, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141224

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1204998

Country of ref document: HK